**CHARITY REGISTRATION NUMBER: 1184699** 

## **OURBRAINBANK CIO** 

## **Unaudited Financial Statements 31 December 2025** 

## **BURGESS HODGSON LIMITED** 

Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN 



## **OURBRAINBANK CIO** 

## **Financial Statements** 

## **Year ended 31 December 2025** 

||**Page**|
|---|---|
|Trustees' annual report|**1**|
|Statement of financial activities|**5**|
|Statement of financial position|**6**|
|Notes to the financial statements|**7**|





## **OURBRAINBANK CIO** 

## **Trustees' Annual Report** 

## **Year ended 31 December 2025** 

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 December 2025. 

## **Reference and administrative details** 

**Registered charity name** OURBRAINBANK CIO **Charity registration number** 1184699 **Principal office** 2 Florida Street London E2 6AL **The trustees** U Yunis F Thorne M J Wilson (Appointed 7 October 2025) A Coulson J Arnold-Forster R Clemmow S D Matthews A Bennett-Clemmow E Pilkington N Nuttall E S Bathers **Accountants** Burgess Hodgson Limited Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN 

**1** 



## **OURBRAINBANK CIO** 

## **Trustees' Annual Report** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **Structure, governance and management** 

OurBrainBank in the UK is governed on a voluntary basis by its experienced UK Board of Trustees, which meets and engages regularly to provide direction, oversight and implementation of the charity's activities in the UK. We work closely with our colleagues at OurBrainBank US, with our UK Trustees joining global board meetings to collaborate across areas of strategic development and communications, operating globally where we can and independently for campaigns that reflect local context. 

OurBrainBank also benefits from robust medical and patient advisors based in the US, co-headed by leading neuro-oncologists Fabio Iwamoto MD of Columbia University, and Lakshmi Nayak MD of Dana-Farber Cancer Institute. The advisors bring together a wide range of clinical specialists spanning neuro-surgery, psychiatry and neuro-oncology. The patient advisors include patients and caregivers. 

In the past few years we have increasingly built links with international GBM medical and patient/carer communities and, in the UK, we have grown relationships with healthcare and wider stakeholders and are regular attendees at GBM and brain cancer-related events. 

We also engage and collaborate with other brain tumour charities in the UK. It has been very important to understand the work that they are undertaking in this space and ensure that we are not duplicating or performing any work that overlaps with their activities. It has been our focus, since the launch of our white paper in 2023 to advocate and campaign alongside other charities for an increase in universal tissue freezing and storage as a basis for genomic sequencing. So it marks progress, and a sign of collaboration, that the issue is now part of the mainstream of GBM discourse and policy. 

## **Objectives and activities** 

Created by the late Jessica Morris as a direct result of her own diagnosis, OurBrainBank is an innovative, patient-led movement designed to move glioblastoma (GBM) from terminal to treatable, powered by patients. 

It is the first non-profit created by, for and with people with GBM, a rare and deadly brain cancer whose 5-year survival rate is 5%. Glioblastomas are the most common high grade (cancerous) primary brain tumour in adults. A glioblastoma is the fastest growing form of glioma brain tumour and is extremely difficult to treat. 

OurBrainBank aims to raise awareness and understanding of GBM, improve standards of patient care and quality of life, and highlight the importance of GBM-focused research and clinical trials. 

The objectives of OurBrainBank are: 

- campaigning for better treatment options for those living with GBM in the UK, in particular advocating for an increase in tissue freezing and genomic medicine. 

- the advancement of the education of the general public in all areas relating to glioblastoma. 

- the advancement of health by the provision of support, assistance and information to persons living with glioblastoma, and by research into the nature, causes, diagnosis and treatment of glioblastoma. 

Globally and in the UK, we engage with GBM patients and their carers through a variety of channels, and use our external channels, fundraising activities, advocacy and campaigning initiatives to reach wider stakeholders. 

**2** 



## **OURBRAINBANK CIO** 

## **Trustees' Annual Report** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **Achievements and performance** 

Throughout 2025 we actively contributed to shaping the stakeholder debate around GBM in the UK. We have been regular attendees and contributors at the All-Party Parliamentary Group on Brain Tumours. We submitted evidence to the report, published in June 2025, from the All-Party Parliamentary Group on Less Survivable Cancers, which urged the UK Government to prioritise faster diagnosis of less survivable cancers. Our chair also joined the Brain Tumour Charity to meet with the Department of Health and Social Care to discuss the barriers and issues facing brain tumour patients and carers. We are also regular attendees at the British Neuro-Oncology Society (BNOS) annual conference, attending again in 2025 to engage with health industry stakeholders and other charities. 

A major focus of our work in 2025 and 2026 has been the creation of a collaborative patient and carer research project, together with a team from Imperial College London. It aims to better understand the experience of adult brain tumour patients from the UK, as well as their attitudes to risk and their experiences of accessing treatment outside of the standard care offered by the NHS. 

We launched the survey at the BNOS conference in London in June 2025 and a quantitative survey has since been completed by more than 130 patients, carers and their families in the UK. In 2026 we have added a qualitative interview study with a UK patients and carers to understand their perspectives, motivations and personal experiences in more depth, adding first-person accounts of NHS care, overseas treatment, cost and risk. 

Alongside this research study we have also commissioned a separate literature review paper from a specialist healthcare, technology and innovation consultancy, mapping the treatments that the survey uncovered, including vaccines, hyperthermia, virotherapy and personalised approaches -against the published evidence base, which we aim to have peer-reviewed and published in a specialist cancer policy journal. 

We again attended BNOS in 2026 to provide the GBM medical community and stakeholders with an update of our research, publishing a poster at the conference, and plan to publish two reports later in 2026 - one covering the patient experience review, and a second covering the literature review. 

## **Financial review** 

OurBrainBank currently has no full-time UK employees, but thanks to the generosity of individual donors and fundraisers, we have generated sufficient funds to undertake all these activities and were supported during 2024/25 by our first part-time Campaign and Communications Manager in the UK, Matthew Wilson who we are delighted to say has since joined us as a Trustee. 

2025 saw a number of generous individual donations and energetic fundraisers in support of OBB UK. For example, Jam Bensilum and Milo Caiger-Smith, our founder Jessica's nephew, completed the Brighton marathon to raise more than £6,000 for OurBrainBank. In 2025 we were also delighted to receive a generous grant from The Foyle Foundation, for which we remain extremely grateful. 

More recently, in 2026 we were also successful in the London Marathon ballot. We were so honoured and delighted by the efforts of Jayden Wilkinson who ran to support us, raising more than £2,600 in the process. 

We are extremely grateful to these and many other donors and fundraisers for their support, which enables us to continue our ambitious work. We hope to use the funds to engage more support to grow our activities and continue our campaigning on behalf of all GBM patients in the UK. 

We look forward to having more to report in our 2026 review. 

**3** 



## **OURBRAINBANK CIO** 

**Trustees' Annual Report** _**(continued)**_ 

## **Year ended 31 December 2025** 

The trustees' annual report was approved on .............................. and signed on behalf of the board of23 October 2026 trustees by: 

J Arnold-Forster Chair and Trustee 

**4** 



## **OURBRAINBANK CIO** 

## **Statement of Financial Activities** 

## **Year ended 31 December 2025** 

|||**2025**|**2025**|2024|
|---|---|---|---|---|
|||Unrestricted|||
|||funds|**Total funds**|Total funds|
||**Note**|**£**|**£**|£|
|**Income and endowments**|||||
|Donations and legacies|**4**|28,786|28,786|27,711|
||||||
|**Total income**||28,786|28,786|27,711|
||||||
|**Expenditure**|||||
|Expenditure on charitable activities|**5,6**|17,276|17,276|20,939|
||||||
|**Total expenditure**||17,276|17,276|20,939|
||||||
||||||
|**Net income and net movement in funds**||11,510|11,510|6,772|
||||||
|**Reconciliation of funds**|||||
|Total funds brought forward||111,317|111,317|104,545|
||||||
|**Total funds carried forward**||122,827|122,827|111,317|
||||||



The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. 

**The notes on pages 7 to 11 form part of these financial statements.** 

**5** 



## **OURBRAINBANK CIO** 

## **Statement of Financial Position** 

## **31 December 2025** 

|||**2025**|2024|
|---|---|---|---|
||**Note**|**£**|£|
|**Current assets**||||
|Debtors|**11**|2,954|3,272|
|Cash at bank and in hand||120,413|108,585|
|||||
|||123,367|111,857|
|**Creditors: amounts falling due within one year**|**12**|540|540|
|||||
|**Net current assets**||122,827|111,317|
|||||
|**Total assets less current liabilities**||122,827|111,317|
|||||
|**Net assets**||122,827|111,317|
|||||
|Unrestricted funds||122,827|111,317|
|||||
|**Total charity funds**|**13**|122,827|111,317|
|||||



These financial statements were approved by the board of trustees and authorised for issue on ........................, and are signed on behalf of the board by:23 October 2026 

J Arnold-Forster Chair and Trustee 

**The notes on pages 7 to 11 form part of these financial statements.** 

**6** 



## **OURBRAINBANK CIO** 

## **Notes to the Financial Statements** 

## **Year ended 31 December 2025** 

## **1. General information** 

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is 2 Florida Street, London, E2 6AL. 

## **2. Statement of compliance** 

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011. 

## **3. Accounting policies** 

## **Basis of preparation** 

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure. 

The financial statements are prepared in sterling, which is the functional currency of the entity. 

## **Going concern** 

There are no material uncertainties about the charity's ability to continue. 

## **Judgements and key sources of estimation uncertainty** 

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. 

## **Foreign currencies** 

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the statement of financial activities. 

## **Fund accounting** 

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes. 

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment. 

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds. 

**7** 



## **OURBRAINBANK CIO** 

## **Notes to the Financial Statements** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **3. Accounting policies** _**(continued)**_ 

## **Incoming resources** 

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income: 

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably. 

- legacy income is recognised when receipt is probable and entitlement is established. 

- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers. 

- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted. 

## **Resources expended** 

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates: 

- expenditure on raising funds includes the costs of all fundraising activities, events, noncharitable trading activities, and the sale of donated goods. 

- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities. 

- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities. 

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis. 

**8** 



## **OURBRAINBANK CIO** 

## **Notes to the Financial Statements** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **3. Accounting policies** _**(continued)**_ 

## **Financial instruments** 

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. 

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. 

Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value. 

## **4. Donations and legacies** 

||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
|---|---|---|---|---|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|**Donations**|||||
|Donations|28,786|28,786|27,711|27,711|
||||||
|**Expenditure on charitable activities by fund type**|||||
||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|Support costs|17,276|17,276|20,939|20,939|
||||||



## **5. Expenditure on charitable activities by fund type** 

## **6. Expenditure on charitable activities by activity type** 

|||**Total funds**|Total fund|
|---|---|---|---|
||Support costs|**2025**|2024|
||£|**£**|£|
|Support costs|16,538|16,538|20,129|
|Governance costs|738|738|810|
|||||
||17,276|17,276|20,939|
|||||
|**Analysis of support costs**||||
||Analysis of|||
||support costs|**Total 2025**|Total 2024|
||£|**£**|£|
|General office|4,502|4,502|1,174|
|Finance costs|(1,084)|(1,084)|(959)|
|Subcontractor|13,120|13,120|19,914|
|||||
||16,538|16,538|20,129|
|||||



## **7. Analysis of support costs** 

**9** 



## **OURBRAINBANK CIO** 

## **Notes to the Financial Statements** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **8. Net income** 

Net income is stated after charging/(crediting): 


**----- Start of picture text -----**<br>
2025 2024<br>£ £<br>Foreign exchange differences 219 (47)<br> <br>**----- End of picture text -----**<br>


## **9. Staff costs** 

The average head count of employees during the year was Nil (2024: Nil). 

No employee received employee benefits of more than £60,000 during the year (2024: Nil). 

## **10. Trustee remuneration and expenses** 

No remuneration or other benefits from employment with the charity or a related entity were received by the trustees. 

## **11. Debtors** 

|||||**2025**|2024|
|---|---|---|---|---|---|
|||||**£**|£|
||Amounts owed by group undertakings|||2,954|3,272|
|||||||
|**12.**|**Creditors:** **amounts falling due within one year**|||||
|||||**2025**|2024|
|||||**£**|£|
||Accruals and deferred income|||540|540|
|||||||
|**13.**|**Analysis of charitable funds**|||||
||**Unrestricted funds**|||||
|||At|||**At**|
|||1 January 202||**31**|**December**|
|||5|Income|Expenditure|**2025**|
|||£|£|£|£|
||General funds|111,317|28,786|(17,276)|122,827|
|||||||
|||At|||At|
|||1 January 202||31|December|
|||4|Income|Expenditure|2024|
|||£|£|£|£|
||General funds|104,545|27,711|(20,939)|111,317|
|||||||



**10** 



## **OURBRAINBANK CIO** 

## **Notes to the Financial Statements** _**(continued)**_ 

## **Year ended 31 December 2025** 

## **14. Analysis of net assets between funds** 

||Unrestricted|**Total Funds**|
|---|---|---|
||Funds|**2025**|
||£|**£**|
|Current assets|123,367|123,367|
|Creditors less than 1 year|(540)|(540)|
||||
|**Net assets**|122,827|122,827|
||||
||Unrestricted|Total Funds|
||Funds|2024|
||£|£|
|Current assets|111,857|111,857|
|Creditors less than 1 year|(540)|(540)|
||||
|**Net assets**|111,317|111,317|
||||



**11** 

